News
Gustave Roussy and LXRepair announce a partnership for personalized radiotherapy of cancer
LXRepair, a pioneer in personalized radiotherapy with functional assays measuring DNA repair to predict treatment response, with a clinical proof-of-concept of radiotoxicity prediction in breast and prostate cancer, and Gustave Roussy, Europe's leading cancer center,...
Amolyt Pharma Announces $80 Million Series B Financing led by Sectoral Asset Management and Andera Partners
Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that the company has closed an $80 million Series B equity financing round. The financing was co-led by Sectoral Asset Management...
Amolyt Pharma to Host Key Opinion Leader Webinar and Discuss Results of Phase I Clinical Trial of AZP-3601 on Friday, October 1st at 10:00am ET
Amolyt Pharma, a global company specializing in developing therapeutic peptides for rare endocrine and related diseases, today announced that it will host a key opinion leader (KOL) webinar on AZP-3601, the Company’s lead product candidate for the potential treatment...
Amolyt Pharma Exercises Option to License Optimized Acromegaly Drug Candidate from PeptiDream as it Continues to Build its Rare Endocrine Pipeline.
Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, and PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (“PeptiDream”)(Tokyo: 4587), today announced that Amolyt Pharma has...
Theranexus and Beyond Batten Disease Foundation (BBDF) win us Investigational New Drug (IND) approval to start clinical development of BBDF 101
Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases, and Beyond Batten Disease Foundation (BBDF), announce receipt of Investigational New Drug (IND) approval from the Food and Drug Administration (FDA) to launch a Phase I/II...
Amoéba : a 2nd cereal trial campaign confirms the potential of its biocontrol product
AMOÉBA (FR0011051598 - ALMIB), producer of a biological biocide capable of eliminating bacterial risk in water and human wounds, and of a biocontrol product for plant protection, still in the development phase, announces the results of the 2nd cereal trial campaign....
Amoeba : Promising results of the Biocontrol-Grapevine application despite a very strong “downy mildew year”
AMOÉBA (FR0011051598 - ALMIB), producer of a biological biocide capable of eliminating bacterial risk in water and human wounds, and of a biocontrol product for plant protection, still in the development phase, announces the results of the third field trial campaign...
Amolyt Pharma Announces Appointment of Two Directors
Amolyt Pharma, a global company specializingin developing therapeutic peptides for rare endocrine and metabolic diseases, today announced that the company has made two appointments to its Board of Directors following its Annual General Meeting, which was held on June...
Lyon-based medtech MexBrain raises nearly €6 million from Arbevel, the French Tech Seed fund and Kreaxi for the clinical development of its medical device
To advance the clinical development of its medical device for the specific extraction of toxic free metals from the blood, MexBrain has announced the raising of 5.75 million euros. This round of financing brings together two institutional investors, Arbevel and...
Theranexus : 2020 full-year results and update on the progress of main programs
Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, today announces its results for the year ending 31 December 2020...